A Novel Systemic siDR6 Delivery System Based on DP7-C for the Treatment of Metastatic Lung Cancer

• DOI: 10.2147/ijn.s488213
• Publication Date: 2025-03-19T07:20:11Z
• Authors: Hongyou Zhou; Rui Zhang; Ke Men; Lin Tang; Yusi Wang; Li Yang

The treatment of metastatic lung cancer, a common complication many primary cancers, has historically been significant clinical challenge. Once metastasis occurs, patients' survival is often significantly shortened. Therefore, prevention and metastases an important aspect cancer treatment. In this study, simple, low-toxicity, cholesterol-modified cationic cell-penetrating peptide DP7 (DP7-C), in combination with siDR6 was used for intravenous administration the metastases. Initially, databases were analyzed to determine expression levels death receptor 6 (DR6) tumors correlation between DR6 patient times. DP7-C/siDR6 micelles prepared by self-assembly method. By cultivating 293T, B16F10 LL2 cells, vitro experiments performed assess transfection efficiency, safety anti-cancer ability DP7-C/siDR6, while its targeting efficiency lungs investigated mouse experiments. Furthermore, therapeutic efficacy demonstrated model situ, artificial metastasis, 4T1 spontaneous metastasis. data analysis revealed that highly expressed majority patients high exhibited shorter showed it could inhibit tumor cell growth suppressing STAT3 signaling pathway. Subsequent resulted efficient targeting. inhibition on endothelial cells found prevent metastasis-induced necrosis thereby preventing And excellent models. systemic delivery DP7-C carrying provide alternative strategy halt